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Abstract
Background & Aims—Chronic hepatitis B virus (HBV) infection is an important cause of 
cirrhosis and hepatocellular carcinoma worldwide; populations that migrate to the US and Canada 
might be disproportionately affected. The Hepatitis B Research Network (HBRN) is a cooperative 
network of investigators from the United States and Canada, created to facilitate clinical, 
therapeutic, and translational research in adults and children with hepatitis B. We describe the 
structure of the network and baseline characteristics of adults with hepatitis B enrolled in the 
network.
Methods—The HBRN collected data on clinical characteristics of 1625 adults with chronic HBV 
infection who are not receiving antiviral therapy from 21 clinical centers in North America.
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Results—Half of the subjects in the HBRN are male, and the mean age is 42 years; 72% are 
Asian, 15% are Black, and 11% are White, with 82% born outside of North America. The most 
common HBV genotype was B (39%); 745 of subjects were negative for the hepatitis B e antigen. 
The median serum level of HBV DNA when the study began was 3.6 log10 IU/mL; 68% of male 
subjects and 67% of female subjects had levels of alanine aminotransferase above the normal 
range.
Conclusions—The HBRN cohort will be used to address important clinical and therapeutic 
questions for North Americans infected with chronic HBV and to guide health policies on HBV 
prevention and management in North America.
Keywords
HBeAg; Chronic hepatitis B virus infection; USA; ALT
Background
Chronic hepatitis B virus (HBV) infection is a common cause of morbidity and mortality in 
the United States (U.S.) and throughout the world.1 Globally, cirrhosis ranks as the twelfth 
leading cause of death2 and chronic HBV infection accounts for approximately a third of 
cases of cirrhosis and half of all hepatocellular carcinomas (HCC).3 Although conventional 
estimates have cited approximately 1.4 million persons in the U.S. to be HBV-infected,4 the 
number of infected persons may be as high as 3 million due to undersampling of immigrant 
populations.5
Despite the availability of an effective vaccine for prevention of hepatitis B and safe and 
effective therapy, many questions regarding the natural history and pathogenesis of chronic 
HBV infection remain unanswered. With substantial racial and ethnic diversity, the U.S. and 
Canadian populations are ideal to study the full breadth of the epidemiology, natural history 
and clinical virology of chronic HBV infection.
The Hepatitis B Research Network (HBRN) is a cooperative network of investigators from 
28 geographically distinct clinical centers across the U.S. and in Canada (North America), a 
data coordinating center (DCC) and an immunology center funded by the National Institute 
of Diabetes and Digestive and Kidney Disease (NIDDK). The goal of the HBRN is to 
facilitate and conduct epidemiological clinical virological and therapeutic research in acute 
and chronic hepatitis B in both adult and pediatric patients who reside in North America. 
This report describes the structure of the HBRN and the baseline characteristics of the 
participants in the Adult Cohort Study.
Methods
Establishment and governance of the HBRN
The HBRN sites were selected through a process of peer review in response to a Request for 
Application issued by the NIDDK. Each Clinical Center Grantee is comprised of 1-3 clinical 
sites resulting in a total of 21 adult and 7 pediatric clinical centers in North America. The 
HBRN also includes a DCC and an Immunology Center (Figure 1). The DCC is responsible 
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for coordinating study operations and logistics, developing and implementing data and other 
systems, maintaining the database, and performing data analyses. The Immunology Center is 
responsible for designing and conducting immunologic studies to elucidate immune 
responses to HBV during different phases of CHB and in response to antiviral therapy. 
There are two central virology laboratories.
The HBRN is funded through cooperative U01 grants with NIDDK officials participating in 
its design and execution. A Steering Committee comprised of the principal investigator (PI) 
of each U01 grant, the PI from the DCC, the PI from the Immunology Center, and the 
NIDDK project scientist is responsible for study oversight. Several subcommittees have 
been established to facilitate the work of the Steering Committee (Figure 2). An independent 
Data and Safety Monitoring Board (DSMB) was appointed by the NIDDK to review the 
protocols and monitor the progress of the studies and participant safety.
The HBRN studies include two Cohort Studies (one for adults and another for children), two 
clinical trials of antiviral therapy in immune tolerant participants (one for adults and one for 
children), and a randomized clinical trial of antiviral therapy in immune active participants 
(adults only). The designs of the cohort studies and the clinical trials in immune tolerant 
participants for adults and children are similar and are available on the HBRN website: 
http://www.hepbnet.org/. Currently, there are 14 approved ancillary studies. All protocols 
were approved by the Steering Committee and the Institutional Review Boards (IRB) 
(Research Ethics Board [REB] in the case of the Toronto site) of the participating sites, and 
all participants provided written informed consent.
Adult Cohort Study Design
This is an observational study of adult patients with chronic HBV infection who are not on 
antiviral treatment. The primary aims of the study are to describe the characteristics of 
participants in a prospectively accrued cohort of chronic HBV infection in North America 
and to identify predictors of disease activation and progression. A secondary goal is to 
identify potential participants for the HBRN clinical trials. HBsAg-positive patients 18 years 
or older were eligible for enrollment after providing written informed consent. Patients with 
a history of hepatic decompensation, HCC, solid organ or bone marrow transplantation, or 
human immunodeficiency virus (HIV) coinfection, and those who were receiving antiviral 
therapy (with the exception of women who were pregnant at the time of enrollment), were 
excluded. Participants were evaluated at enrollment, Week 12, Week 24, and every 24 
weeks thereafter. Participants experiencing hepatitis flares, HBeAg or HBsAg loss, or who 
were pregnant were seen at more frequent intervals.
Baseline and Follow-up Evaluation
The baseline evaluation includes a detailed medical history, physical examination, and 
laboratory tests. Information on risk factors for HBV infection, family history of HBV, prior 
antiviral therapy, results of recent imaging tests, medical comorbidities, health behavior and 
socio-economic indicators were recorded. Recommended laboratory tests include complete 
blood count, liver panel, creatinine, INR, alpha fetoprotein (AFP), quantitative HBV DNA 
level, HBsAg, antibody against HBsAg (anti-HBs), hepatitis B e antigen (HBeAg), antibody 
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against HBeAg (anti-HBe), antibody against HIV (anti-HIV), antibody against hepatitis C 
virus (anti-HCV), antibody against hepatitis D virus (anti-HDV), autoimmune markers, and 
fasting glucose and lipid panel. Evaluations at follow up visits include an updated medical 
history, use of HBV antiviral therapy which may have been initiated after entry into the 
cohort, physical examination, laboratory testing for HBV DNA and a liver panel, and results 
of recent imaging tests.
Collection and Storage of Biospecimens
Serum and plasma samples for future research are drawn at each visit, stored frozen at each 
clinical center and sent regularly to the NIDDK central repository where they are stored at 
-80°C. Samples are sent by the repository in batches to central laboratories for testing. One 
sample of whole blood for extracting host DNA is collected from all consenting participants 
for genetic testing. Liver biopsy slides, either historical or from a standard of care biopsy, 
and a sample of liver tissue stored in RNALater if a biopsy was performed during the study, 
are collected from all consenting participants. Data are collected at each clinical site and 
entered into a password protected electronic database by trained personnel. The DCC 
regularly monitors the data to assess the accuracy and timeliness of data collection. Eleven 
of the 21 clinical sites enrolling adults are also engaged in ancillary immunology studies. 
Participants eligible for the immunology studies are enrolled after providing a separate 
written consent.
Enrollment Process and Criteria
The study set out to enroll consecutive, eligible HBsAg-positive patients at each clinical site 
with an aggregate target sample size of 2,500 subjects. At each site, a screening log is kept 
to record reasons for non-enrollment. The first participant was enrolled on January 14, 2011. 
After enrolling approximately 1,500 participants, the Steering Committee reviewed revised 
power calculations and changed from consecutive to targeted enrollment focusing on the 
following groups: (1) potential candidates for the clinical trials, (2) patients who were 
pregnant, (3) individuals who experienced flares of chronic hepatitis B, (4) patients with 
acute hepatitis B, (5) those with known HDV infection, and (6) patients who are eligible for 
the immunology study. The protocol amendment was approved at all sites in 2013. Only 
participants with chronic HBV infection enrolled prior to switching to targeted enrollment 
are included in the current analysis.
Monitoring and Testing
Standardized cutoffs for upper limit of normal (ULN) for ALT of 30 U/L for men and 20 
U/L for women are used, regardless of the normal range at the laboratory from which results 
are obtained. HBV DNA levels from the Central Virology Laboratory are based on results of 
the Roche real-time PCR assay (COBAS Ampliprep/COBAS Taqman HBV Test, v2.0), 
which has a lower and upper limit of quantification of 20 IU/mL and 1.7 × 108 IU/mL, 
respectively. HBV genotype data are based on mass spectrometry, performed at the 
Molecular Epidemiology and Bioinformatics Laboratory in the Division of Viral Hepatitis, 
Centers for Disease Control and Prevention (CDC).6 If there are insufficient research blood 
samples for baseline HBV DNA testing or HBV genotyping to be done in the central 
laboratories, historical results from the medical record are used, if available. Because this is 
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an observational study with study visits conducted in conjunction with clinical practice, 
laboratory tests are not always done on the same day as the study visits. Often, they are done 
prior to the visit so a window of up to 12 months is accepted for baseline ALT and HBV 
DNA and a window of up to 24 months is accepted for HBeAg status. However, reported 
results are typically more recent, i.e., 99% of ALT and HBV DNA is obtained within 3 
months of entry and for HBeAg, 91% are within 12 months of entry.
Assignment of CHB Phenotype
Investigators are asked to assign a phenotype for each participant on the day of enrollment. 
The guidelines are:
1. Immune tolerant: HBeAg-positive, ALT levels ≤ULN on ≥2 occasions at least 6 
months apart and HBV DNA levels ≥106 IU/mL
2. Immune active chronic hepatitis B (CHB)
a. HBeAg-positive: ALT levels >2x ULN on ≥2 occasions at least 6 months 
apart and HBV DNA levels ≥104 IU/mL; or
b. HBeAg-negative: ALT levels >2x ULN on ≥2 occasions at least 6 months 
apart and HBV DNA levels ≥103 IU/mL
c. Inactive carrier: HBeAg-negative, ALT levels ≤ULN and HBV DNA levels 
<103 IU/mL on ≥2 occasions at least 6 months apart.
d. Indeterminate: Individuals who did not fit into one of these categories.
Statistical Analysis
Baseline characteristics were summarized via frequencies and percentages for categorical 
variables and medians and quartiles for continuous variables. To test whether distributions 
of categorical variables differed across racial groups, the Pearson's Chi-square test or its 
exact version were used, as appropriate. Because the results are descriptive, pairwise 
comparisons were not adjusted for multiple testing. The same method was used to examine 
the association between genotype distributions and birthplace. The Kruskal-Wallis test was 
used to test whether the distributions of continuous variables differed across racial groups. 
For all statistical tests, the significance level of 0.05 was used to establish statistical 
significance. The statistical analyses were conducted in SAS (version 9.2, SAS Institute).
Results
Baseline Demographics and Clinical Characteristics of the Adult Cohort
Among 7,118 adults screened for entry into the observational study prior to targeted 
enrollment, 1,653 (23%) were enrolled between January 2011 and August 2013. The major 
reasons for non-enrollment included current antiviral therapy (n=3,013), refusal to consent 
(n=924), inability to comply with follow-up (n=419), and ineligibility due to HIV co-
infection (n=194), HCC (n=188), hepatic decompensation (n=180), liver transplantation 
(n=62), or other reasons (n=951). Twenty-eight subjects with acute hepatitis B are excluded 
from the current analyses resulting in 1625 subjects with chronic HBV infection in the 
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cohort. The median age was 42 years (range 18-80 years), 51% were male, and median 
physician-estimated duration of infection was 31 years (range 1-76 years). As shown in 
Table 1, the majority of subjects were Asian (72%), followed by Black (15%), White (11%), 
and mixed or other race (2%). Less than one-fifth (18%) of the subjects were born in North 
America. For the 1,210 (74%) participants for whom a route of transmission was determined 
by the investigator, it was broadly categorized as vertical in 60% and horizontal in 40%. The 
distribution of HBV genotypes were A 18%, B 39%, C 33%, D 8%, E 3% and other 1%. At 
baseline, 74% of the subjects were negative for HBeAg. Median serum HBV DNA level 
was 3.6 log10 IU/ml with 36% <103 IU/mL, 21% 103-104 IU/mL, 25% 104-107 IU/mL and 
18% ≥107 IU/mL. The distribution of serum ALT levels was ≤1x ULN in 33%, >1 to ≤2x 
ULN in 43% and >2x ULN in 24%. Physician assigned phenotype at study entry was 
reported as immune tolerant in 10%, HBeAg positive CHB in 14%, HBeAg negative CHB 
in 26%, inactive carrier in 37% and indeterminate in 13%. Most participants (86%) had 
never received treatment for HBV infection.
Analysis by Race
There were marked differences in almost all of the demographic, clinical and laboratory 
features among the major racial groups (Table 1). Compared to Asians, Whites and Blacks 
were older, more likely to be male and have a shorter estimated-duration of infection. 
Vertical transmission was the predominant source of infection among Asians whereas 
horizontal transmission was more common among Whites and Blacks, with sexual 
transmission and medical exposure being the most common modes of horizontal 
transmission. A majority of all races were HBeAg negative, including 70% of Asians, 80% 
of Whites and 90% of Blacks. The distribution of HBV genotypes varied markedly among 
the 3 major racial groups. The predominant genotypes among Asians were B (50%) and C 
(41%), among Whites A (55%) and D (33%) and among Blacks A (65%) and E (19%). The 
majority of Whites in the cohort (65%) were born in North America compared to only 24% 
of Blacks and 8% of Asians.
ALT levels were also different across racial groups (p=0.01, Table 1 and Figure 3a). A 
higher percentage of Blacks (42%) than Asians (32%, p=0.01) or Whites (24%, p=0.001) 
had normal ALT, and proportionally more Whites (31%) had an elevated ALT level >2x 
ULN compared to Asians (24%, p=0.05) and Blacks (20%, p=0.02). HBV DNA levels were 
highest among Asians (Table 1 and Figure 3b). Physician-assigned phenotype differed by 
race (Figure 4). Among Asians, 13% were designated as having immune tolerant disease, 
29% had HBeAg negative CHB, 15% had HBeAg positive CHB and 30% were inactive 
carriers. In contrast, among Whites and Blacks, immune tolerant disease was uncommon 
(1% and 2%) and the inactive carrier phenotype was the most common (47% and 66%, 
respectively) followed by HBeAg negative CHB (25% and 14%, respectively). Notably, 
13% (10-15% by race) of all participants had an indeterminate phenotype. Among 
participants with an indeterminate phenotype for whom each characteristic was known, 57% 
were male, 74% Asian and 83% were HBeAg negative. There was a broad spread of HBV 
DNA levels with 33% <103 IU/mL, 27% 103-<104 IU/mL, 34% 104-<107 IU/mL and 5% 
>107 IU/ml and ALT levels, 28% had an ALT ≤ULN, 54% >1-2x ULN and 18% >2x ULN.
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Analysis by Continent of Birth
There were also racial and genotype differences with respect to immigration status. Nearly 
three-quarters of the participants in the HBRN adult cohort were Asians of whom 92% were 
born outside North America. In addition, 15% of the cohort was Black of whom 70% 
reported Africa as their birthplace. The genotype distribution differed significantly (p<.001) 
by Continent of birth (Figure 5). The most common genotypes were A and C among those 
born in the U.S. and Canada, B and C for those born in Asia, A and E in those born in 
Africa, A and D in those born in Europe, and A and others (F, G and H) for those born in 
South America and Mexico.
Discussion
The objectives, organizational structure, and initial findings of the NIDDK-sponsored 
HBRN are described in this report. The HBRN is the largest research program in North 
America created to study the epidemiology, natural history, and treatment of CHB. During a 
period of 32 months, 1,625 adults with chronic HBV infection were enrolled from 21 
clinical centers in the United States and Canada. The potential importance of the HBRN is 
due to its wide catchment distribution, the racial and ethnic diversity of the participants, the 
planned long-term follow up of study participants, and the breadth of data and biosamples 
collected which will enable investigators to study a wide range of topics related to hepatitis 
B. Efforts will continue to enroll targeted patient groups for studies of specific aspects of 
natural history of chronic HBV infection and treatment trials. Information on pediatric 
participants enrolled in the HBRN cohort studies will be analyzed and published separately.7
While it is generally accepted that chronic HBV infection can be classified into four phases, 
13% of subjects in the HBRN did not meet criteria for any of these phases. Intriguingly, 
using recent definitions of ‘normal’ ALT instead of laboratory reference ranges, 43% of our 
cohort displayed low level elevations in ALT (1-2x ULN) that may not be neatly categorized 
into commonly accepted immune active, inactive or tolerant phases of chronic HBV 
infection. Further follow-up will determine the natural history of these participants. 
Furthermore, virtually all of the immune tolerant patients were Asian and were born abroad.
One of the phases, HBeAg-negative CHB, was formerly considered relatively rare in North 
America and has been observed more commonly in the Mediterranean, Eastern Europe and 
Asia where it may constitute as much as 90% of all patients with chronic HBV infection.8,9 
Our study showed that in North America, HBeAg-negative CHB is far more common than 
HBeAg-positive CHB among all racial groups. The largest group of HBeAg negative 
participants was classified as inactive carriers; excluding patients who were receiving 
antiviral therapy may have skewed the HBRN cohort towards this group.
Determining HBV genotypes is an important goal of the HBRN as it has been postulated 
that certain genotypes are associated with a higher incidence of long term complications 
including HCC.10 A broad range of genotypes (A to H) are represented in the HBRN cohort 
with genotypes A-D constituting more than 90% of cases. Compared to a previous study 
done a decade ago, the most striking difference of the current analysis is the markedly lower 
prevalence of genotype A (a decline from 35% to 18%) and increase in genotype B (from 
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22% to 39%).11 This could be due to the study being conducted at different sites than 
previous or participant selection, but could also be explained by changes in immigration 
patterns over the last decade.
The adult cohort study provides a unique opportunity to examine the natural history of 
hepatitis B across many races and ethnicity. The data on country of birth confirms that the 
burden of chronic HBV infection is disproportionately large among immigrant populations 
residing in North America, the size of which differs by race. These findings from the HBRN 
are well aligned with a recent report from the Centers for Disease Control and Prevention 
highlighting the impact that changing immigration patterns has had on the epidemiology of 
chronic HBV infection in the U.S. It is estimated that more than 90% of people with chronic 
HBV infection in the U.S. today immigrated from other countries.12 During the period from 
1974-2008, nearly 30 million immigrants have entered the U.S. of whom 63% were born in 
countries of intermediate or high HBV prevalence (range 2-31%).12 Thus, it is estimated 
that 1.3 million new HBsAg carriers entered the U.S. during this period. The true burden of 
HBV infection in the U.S. has been under-appreciated because immigrant minorities are 
inadequately sampled in population-based studies such as the National Health and Nutrition 
Examination Survey IV study.13 The high frequency of imported chronic hepatitis B has 
important implications for developing public health strategies to educate and control spread 
of HBV infection in the community.
There are several limitations of the HBRN worth noting. Subjects enrolled in the HBRN 
may not be representative of those in the community. Patients who are currently on antiviral 
therapy (>40% of those screened for enrollment), those who do not have access to 
specialized liver centers and those who do not speak a language for which data can be 
collected by the HBRN were not included. Furthermore, over half of the potentially eligible 
participants were not enrolled, primarily because they refused to consent or were considered 
to be unable to comply with follow-up. Subjects with HIV were excluded from the main 
cohort, but are being studied as part of a parallel NIDDK R01 funded ancillary study.
In summary, the NIDDK-sponsored HBRN is the largest prospective cohort study in North 
America, and includes a diverse racial distribution and the full spectrum of disease 
phenotypes.5,14 Longitudinal assessments of participants should provide meaningful insights 
into the natural history and disease burden of chronic HBV infection in North America. 
With the large size of the population under study, the HBRN should provide reliable 
estimates of transitions from one phase of chronic HBV infection to another and the 
virologic and immunologic basis behind those transitions. Collectively, immigrants with 
chronic HBV infection constitute the largest group of patients with hepatitis B in North 
America. A better understanding of the epidemiology and natural history could improve 
management, delay disease progression and save lives.
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HBV hepatitis B virus
U.S. United States
HCC hepatocellular carcinoma
HBRN Hepatitis B Research Network
NIDDK National Institute of Diabetes and Digestive and Kidney Diseases
DCC Data Coordinating Center
DNA deoxyribonucleic acid
HBsAg hepatitis B surface antigen
HBeAg hepatitis B e antigen
DSMB Data and Safety Monitoring Board
ALT alanine aminotransferase
anti-HBe antibody to HBeAg
anti-HIV antibody to human immunodeficiency virus
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anti-HCV antibody to hepatitis C virus
anti-HDV antibody to hepatitis D virus
PCR polymerase chain reaction
AST aspartate aminotransferase
anti-HBs antibody to HBsAg
CHB chronic hepatitis B
NIH National Institutes of Health
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Map indicating location of clinical sites (blue circles, orange diamonds and green square), 
DCC (red balloon), Immunology Center (yellow arrowhead) comprising the HBRN and the 
funding agency, NIDDK (same location as NIH clinical center).
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Organizational Structure of HBRN. The Hepatitis B Research Network (HBRN) consists of 
21 clinical sites recruiting adults, a data coordinating center, an immunology center, and the 
Liver Disease Branch at NIDDK. A Steering Committee is responsible for study oversight. 
Several committees were established and an independent Data and Safety Monitoring Board 
(DSMB), appointed by NIDDK, reviewed the protocols and the progress of the studies.
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Distribution of serum ALT (categorized by upper limit of normal) by race. Serum ALT was 
categorized as ≤1 x ULN, >1 to 2 x ULN and >2 x ULN, with ULN defined as 30 U/L for 
men and 20 U/L for women.
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Distribution of serum HBV DNA level by race. Serum HBV DNA was categorized as <103 
IU/mL, 103 to 104 IU/ml, 104 to 107 IU/mL and ≥107 IU/mL.
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Distribution of phases of chronic HBV infection by race. Each slice of the pie represents the 
percent phenotype distribution.
Ghany et al. Page 17























Distribution of subjects in the HBRN Cohort Study by Continent of birth and HBV 
genotype. The size of each pie represents the proportion of enrollees who were born in each 
continent (with the exception of Europe and South America-which were enlarged slightly to 
facilitate viewing) and each slice of the pie represents the percent genotype distribution.
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